Imatinib mesylate (IM) therapy is effective in patients with chronic myeloid leukemia (CML). However, whether it should he discontinued in patients who achieve sustained molecular response is debated. We describe 4 patients with undetectable levels of BCR-ABL transcripts in whom IM therapy was discontinued. Two patients relapsed after 7 and 10 months and promptly responded after restarting therapy; 2 patients are off therapy at the last follow-up visit after 14 and 15 months and are still in complete molecular remission.
|Number of pages||3|
|Publication status||Published - Jul 2005|
- Chronic myeloid leukemia
- Therapy discontinuation
ASJC Scopus subject areas